INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Inovio Pharmaceuticals, Inc. - INO

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Inovio Pharmaceuticals and its executives following the FDA's rejection of the company's request for accelerated approval of its treatment INO-3107 [1][3]. Group 1: FDA Announcement - On December 29, 2025, the FDA accepted Inovio's Biologics License Application (BLA) for INO-3107, a treatment for recurrent respiratory papillomatosis, but did not find sufficient information for accelerated approval [3]. - Inovio announced it does not plan to pursue approval under the standard review timeline and intends to meet with the FDA to discuss options for accelerated approval [3]. Group 2: Stock Market Reaction - Following the FDA announcement, Inovio's stock price dropped by $0.56 per share, representing a decline of 24.45%, closing at $2.29 per share on December 29, 2025 [4].